ASP Isotopes Inc. Common Stock (ASPI) | The Buildout — AI Infrastructure
The Verdict
ASP Isotopes develops and operates isotope enrichment facilities that produce high-purity materials. Silicon‑28 enrichment targets advanced semiconductor manufacturing, offering improved thermal conductivity and electron mobility for cutting‑edge AI chips. Beyond silicon, the company produces Carbon‑14 and Ytterbium‑176 for nuclear medicine, and is developing high‑assay low‑enriched uranium for next‑generation nuclear reactors. The AI exposure is via a semiconductor supply chain that demands better materials as chip performance pushes physical limits.
| Market Cap | — |
| Revenue (TTM) | $27M |
| Revenue Growth | +513.6% |
| EBITDA Margin (TTM) | -256.7% |
| Net Cash | $29M |
| Earnings Beats | 0 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Enrichment plants are capital efficient: Yb‑176 plant cost ~$3M and built in two months, enabling rapid scaling without large dilutive funding.
- TerraPower HALEU contract: 10‑year, up to 150 metric tons, de‑risking the Nuclear Fuels segment and providing a long‑dated revenue anchor.
- Strong balance sheet with $200.1M cash as of Q1 2026, covering years of operating costs.
- Three enrichment plants built and producing, demonstrating core technical capability.
- Low‑capex model and modular plant design create a barrier to entry for competitors without similar technology.
What We’re Watching
- NNR regulatory approval for Pelindaba uranium test benches — timing uncertain, key to HALEU validation.
- Commercial shipment timing: C‑14 mid‑2026, Si‑28 Q3 2026, Yb‑176 mid/Q3 2026 — any further slips would push out revenue and cash‑flow breakeven.
- Customer conversion risk: Yb‑176 customers need to evaluate samples before signing supply agreements; no firm contracts yet.
- Laser export permits for next‑gen isotope plants (Ni‑64, Gd‑160, Li‑6) — no timeline, significant delay risk.
The technical thesis is intact — all three enrichment plants have been built and are now producing material. However, the commercial thesis is unproven; repeated shipment delays and an absence of revenue raise questions about management's ability to deliver on timelines. The key open question is whether mid‑2026 to Q3 2026 commercial shipments will land on time and convert into recurring revenue.
Earnings
ASPI reported Q1 FY2026 revenue of $4.2 million and a gross margin of 39.9%, with EBITDA of negative $21.8 million. The newly acquired helium and LNG business contributed $0.6 million, or 15 % of the quarter’s total, while the remaining revenue derived from PET Labs and construction services.
| Metric | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $4M | $17M | $1M | +281.8% |
| Gross margin | 39.9% | 12.5% | 29.7% | +1020bps |
| EBITDA | −$22M | −$21M | −$8M | +179.5% |
| EPS | $-0.06 | $-0.84 | $-0.12 | −52.8% |
Management tone: No earnings call on record for the latest period.
Management Guidance
No guidance was issued.
Trajectory
Revenue has been lumpy, swinging from a low of $1.0 million in Q2 FY2024 to $16.7 million in Q4 FY2025, driven primarily by construction services and, more recently, the January 2026 acquisition of the helium and LNG business. The core isotope enrichment plants have yet to generate material revenue, so the P&L remains dominated by low‑margin construction and one‑time contributions. Gross margins ranged from 8.7 % to 50.7 % in recent quarters, reflecting the mix shift. The cash burn remains high, with EBITDA losses averaging around $20 million per quarter in the last three reported periods.
The Model
The model projects FY+1 revenue of $30 million and EBITDA of negative $75 million, reflecting the early stages of commercial isotope shipment ramp. By FY+2, revenue climbs to $65 million with improving EBITDA of negative $43 million, as higher‑margin isotope sales (C‑14, Yb‑176, Si‑28) begin to offset start‑up costs and low‑margin construction revenue. The trajectory hinges on the timing and volume of first shipments and the conversion of discussions into firm orders.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $24M | $30M | $65M |
| YoY Growth | — | +25.5% | +116.7% |
| EBITDA | −$55M | −$75M | −$43M |
| EBITDA Margin | -231.4% | -250.0% | -66.7% |
Projections are the median of 5 independent model runs.
No guidance was issued.
What Could Go Right — and Wrong
- Successful on‑time shipments of C‑14, Si‑28, and Yb‑176 in mid‑2026 to Q3 2026, converting contracts into high‑margin revenue.
- Yb‑176 customer sample evaluations lead to multi‑year supply agreements at $20k/gram, driving rapid revenue growth.
- NNR approval and successful HALEU test enrichment at Pelindaba validate QLE technology for the nuclear fuel market.
- Noble Africa/ENDRA merger closes and the $50M placement creates a publicly traded helium platform, unlocking value.
- Si‑28 achieves commercial adoption and a path to $20/gram, attracting high‑volume orders from major semiconductor fabs.
- Further shipment delays push cash‑flow breakeven beyond 2027, eroding the cash cushion.
- Key customer loss or cancellation of the C‑14 tolling agreement or TerraPower HALEU contract.
- Regulatory rejection or indefinite delay of Pelindaba laser enrichment testing.
- Si‑28 demand fails to materialize, leaving the semiconductor isotope as a negligible revenue contributor.
- Centrus or government‑subsidized competitors lock up HALEU offtake, reducing ASPI’s addressable market.
Looking Ahead
Over the next twelve months, ASPI aims to deliver first commercial shipments from its three enrichment plants — C‑14 (mid‑2026), Yb‑176 (mid‑2026/Q3 2026), and Si‑28 (Q3 2026) — which would mark the transition to revenue generation. The Noble Africa/ENDRA merger and $50M placement are expected to close, surfacing value in the helium business. Meanwhile, regulatory outcomes at Pelindaba and progress on laser export permits for next‑gen plants will shape the growth path beyond 2026.
- Mid‑2026First C‑14 commercial shipment — Tests whether the take‑or‑pay tolling agreement delivers as planned, starting isotope revenue.
- Mid‑2026 / Q3 2026First Yb‑176 commercial shipment — Checks customer acceptance and conversion to multi‑year supply agreements.
- Q3 2026First Si‑28 commercial shipment — Validates technical readiness and initial demand from U.S. semiconductor buyers.
- Announced Jun 2026, closing TBDNoble Africa/ENDRA merger close — Unlocks helium platform value and brings in $50M capital.
- Timing unclearPelindaba NNR approval and test enrichment — Opens the nuclear fuels segment to HALEU development.
- Pending export permitsNext‑gen isotope plant starts (Ni‑64, Gd‑160, Li‑6) — Determines expansion beyond current three isotopes.
Financials
Annual Summary
| Metric | FY2025 | TTM |
|---|---|---|
| Revenue | $24M | $27M |
| Gross Margin | 24.6% | 17.6% |
| EBITDA | −$55M | −$97M |
| EBITDA Margin | -231.4% | -256.7% |
| Net Income | −$175M | −$174M |
| Free Cash Flow | −$47M | −$95M |
| Net Cash | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)17.6%
- EBITDA Margin (TTM)-256.7%
- Net Margin (TTM)-643.0%
- ROIC-22.5%
- SBC / Revenue68.5%
The Company
ASP Isotopes uses proprietary aerodynamic and laser enrichment technologies to produce high‑purity isotopes. Its products include Carbon‑14 and Ytterbium‑176 for nuclear medicine, Silicon‑28 for advanced semiconductor manufacturing, and — through its Quantum Leap Energy subsidiary — high‑assay low‑enriched uranium for next‑generation nuclear reactors. The Silicon‑28 link to AI infrastructure is indirect but real: enriched silicon improves heat dissipation and electron mobility in chips, addressing a key scaling challenge.
The company operates largely in South Africa, with enrichment plants in Pretoria and a test facility at the Necsa Pelindaba site. It recently acquired a helium and LNG production asset (Virginia Gas Plant) via Renergen. ASPI’s model is capital‑efficient: it builds modular, low‑cost plants using off‑the‑shelf lasers, which allows rapid deployment and expansion. Management emphasizes in‑house engineering talent, with over 150 employees solving technical challenges internally, and partners with state‑owned entities like Necsa for regulatory and infrastructure support.
Business Segments
Competitive Landscape
ASPI competes in two distinct arenas: isotope enrichment for medical and semiconductor applications, and nuclear fuel for advanced reactors. In HALEU, it faces entrenched centrifuge‑based competitors like Centrus, which has government backing and a large backlog, and Cameco’s GLE laser project. In specialty isotopes, few competitors offer Yb‑176 or Si‑28 at commercial scale, giving ASPI a first‑mover advantage, though the market is nascent and customer qualification hurdles are high.
- Centrus Energy (LEU)Dominant U.S. centrifuge‑based HALEU enricher with $3.9B backlog and $900M DOE award; management sees government subsidies as a competitive threat to ASPI’s capex advantage.
- Cameco (CCJ)Partner in the Global Laser Enrichment (GLE) project, which could compete with ASPI’s QLE technology for uranium enrichment; GLE is focused on DOE tails, not yet commercial HALEU.
Supply Chain
ASPI sits at the enrichment stage of the isotope supply chain, sourcing raw materials and off‑the‑shelf lasers, then purifying isotopes for pharmaceuticals, semiconductor fabs, and nuclear reactor developers.
More on ASPI: Earnings preview